Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 03, 2022 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Host Second Quarter 2022 Conference Call on August 8, 2022 and Present at Upcoming Conferences

CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
July 22, 2022 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Chief People Officer Carla Poulson Named One of Savoy Magazine’s 2022 Most Influential Black Executives in Corporate America

CAMBRIDGE, Mass., July 22, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
July 08, 2022 16:05 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
June 03, 2022 16:05 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
May 26, 2022 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
May 19, 2022 07:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces FDA Grant of Orphan Drug Designation to XMT-2056 for the Treatment of Gastric Cancer

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
May 09, 2022 07:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results

Advanced UpRi development across UPLIFT, UPGRADE, and UP-NEXT clinical trialsPrepared for expected initiation of patient dosing in Phase 1 clinical trials of XMT-1660 and XMT-2056 in mid-2022Entered...
May 06, 2022 16:05 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
May 02, 2022 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Host First Quarter 2022 Conference Call on May 9, 2022

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
April 06, 2022 16:05 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...